Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
NYR-BI03's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for NYR-BI03. Showing past 6 months and next 12 months · 10 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| NYR-BI03 | Nyrada | Small Molecule Other | Phase 1 | 0 | ||||
| Ketamine in Acute Brain Injury Patients. | Geert Meyfroidt, MD, PhD | Small Molecule Other | Phase 4 | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
| Mechanism | Speed to patient | Manufacturing | Best approved result | Durability | Moat |
|---|---|---|---|---|---|
| Mesenchymal Stem CellAllo MSC | Off-the-shelf | Batch (donor) | Ryoncil (GvHD only) | Transient | Low |
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide | Wake Forest University Health Sciences | Small Molecule Other | Phase 4 | — | — | — | — | — |
| Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) | Anhui Provincial Hospital | Small Molecule Other | Phase 4 | — | — | — | — | — |
| Methylprednisolone for Moderate to Severe Traumatic Brain Injury | Zhangjiagang First People's Hospital | Small Molecule Other | Phase 4 | — | — | — | — | — |
| Buspirone and Melatonin for Depression Following Traumatic Brain Injury | Massachusetts General Hospital | Small Molecule Other | Phase 4 | — | — | — | — | — |
| The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury | Rigshospitalet, Denmark | Other | Phase 4 | — | — | — | — | — |
| Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury | Merz Pharmaceuticals GmbH | Small Molecule Other | Phase 3 | — | — | — | — | — |
| Role of Non-Selective Beta-Adrenergic Blocker in Severe TBI | Tanta University | Small Molecule Other | Phase 3 | — | — | — | — | — |
| Pharmacological Management of Seizures Post Traumatic Brain Injury | Cambridge University Hospitals NHS Foundation Trust | Other | Phase 3 | — | — | — | — | — |
| Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury in Older Adults | London School of Hygiene and Tropical Medicine | Other | Phase 3 | — | — | — | — | — |
| ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients | Australian and New Zealand Intensive Care Research Centre | Small Molecule Other | Phase 3 | — | — | — | — | — |
| Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | VA Office of Research and Development | Small Molecule Other | Phase 3 | — | — | — | — | — |
| Tranexamic Acid in Traumatic Brain Injury | Assiut University | Small Molecule Other | Phase 3 | — | — | — | — | — |
| Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI) | Foundation for Advancing Veterans' Health Research | Small Molecule Other | Phase 3 | — | — | — | — | — |
| Efficacy of Early Continuous Infusion of HSS on the Neurological Outcome at 6 Months in TBI Patients. | Nantes University Hospital | Other | Phase 3 | — | — | — | — | — |
| Hyperbaric Oxygen Treatment for Veterans With Traumatic Brain Injury | University of South Florida | Other | Phase 3 | — | — | — | — | — |
| Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics | Sherief Abd-Elsalam | Other | Phase 3 | — | — | — | — | — |
| Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: An Efficacy Study | Daniel Nishijima, MD, MAS | Small Molecule Other | Phase 3 | — | — | — | — | — |
| Memantine as an Additive Therapy in Patients With Traumatic Brain Injury | Mansoura University | Small Molecule Other | PHASE2/PHASE3 | — | — | — | — | — |
| Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Small Molecule Other | PHASE2/PHASE3 | — | — | — | — | — |
| FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial | Northwestern University | Other | PHASE2/PHASE3 | — | — | — | — | — |
| Valproic AcId for Traumatic BRAin INjury Trial | Northwestern University | Small Molecule Other | PHASE2/PHASE3 | — | — | — | — | — |
| Autologous Stem Cell Study for Adult TBI (Phase 2b) | The University of Texas Health Science Center, Houston | Mesenchymal Stem Cell | Phase 2 | — | — | — | — | — |
| Mesenchymal Stromal Cells for Traumatic Brain Injury | Fondazione IRCCS San Gerardo dei Tintori | Mesenchymal Stem Cell | Phase 2 | — | — | — | — | — |
| Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI). | SHINKEI Therapeutics, Inc | Small Molecule Other | Phase 2 | — | — | — | — | — |
| A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury | Oragenics, Inc. | Other | Phase 2 | — | — | — | — | — |
| Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI | NYU Langone Health | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI | Henry M. Jackson Foundation for the Advancement of Military Medicine | Monoclonal antibody | Phase 2 | — | — | — | — | — |
| Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions | Tang-Du Hospital | Kinase Inhibitor | Phase 2 | — | — | — | — | — |
| BCAAs in Concussion 2.0 | Akiva Cohen | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Improving Neurotrauma by Depolarization Inhibition With Combination Therapy (INDICT) | University of Cincinnati | Other | Phase 2 | — | — | — | — | — |
| Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A) | University of Miami | Other | Phase 2 | — | — | — | — | — |
| Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury | Hope Biosciences LLC | Mesenchymal Stem Cell | Phase 2 | — | — | — | — | — |
| Antisecretory Factor In Severe Traumatic Brain Injury | Peter Siesjö | Peptide Therapeutic | Phase 2 | — | — | — | — | — |
| Allopregnanolone in Chronic Complex Traumatic Brain Injury | VA Office of Research and Development | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Effects of Intravascular Administration of Mesenchymal Stromal Cells Derived from Wharton's Jelly of the Umbilical Cord on Systemic Immunomodulation and Neuroinflammation After Traumatic Brain Injury. | Assistance Publique - Hôpitaux de Paris | Mesenchymal Stem Cell | Phase 2 | — | — | — | — | — |
| Ketamine, SGB and Combination Treatment for TBI | Northwestern University | Other | Phase 2 | — | — | — | — | — |
| Sildenafil for Microvasculopathy in Chronic TBI | University of Pennsylvania | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain Injury | University of Pennsylvania | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury | University of California, San Francisco | Other | Phase 2 | — | — | — | — | — |
| Vitamin D3 for Moderate to Mild Traumatic Brain Injury: A Randomized Trial on Inflammation and Recovery (VIMOT) | Lagos State University | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Sodium Lactate in Severe TBI | University of California, Los Angeles | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Evaluating the Effect of Tranexamic Acid on the Clinical Outcomes in Patients With Traumatic Brain Injury | Mansoura University | Small Molecule Other | PHASE1/PHASE2 | — | — | — | — | — |
| Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury | University of Arizona | Small Molecule Other | PHASE1/PHASE2 | — | — | — | — | — |